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Perspectives on Using Physcomitrella Patens 
as an Alternative Production Platform for Thapsigargin 
and Other Terpenoid Drug Candidates
Henrik Toft Simonsen, Damian Paul Drew and Christina Lunde
VKR Research Centre Pro-Active Plants, Department of Plant Biology and Biotechnology, Faculty 
of Life Sciences, University of Copenhagen, Thorvaldsensvej 40, 1871 Frederiksberg C, Denmark.
Abstract: To overcome the potential future demand for terpenoids used as drugs, a new production platform is currently 
being established in our laboratory. The moss Physcomitrella has been chosen as the candidate organism for production of 
drug candidates based on terpenoids derived from plants, with a primary focus on the sesquiterpene lactone, thapsigargin. 
This drug candidate and other candidates/drugs with sesquiterpene skeleton are diffi cult to obtain by chemical synthesis due 
to their large number of chiral centers. Furthermore, they are not available in suffi cient amounts from their original plant. 
The requirement for a new production system to meet the potential market demand for these compounds is not only obvious, 
but also essential if suffi cient quantities of the drug candidates are to be available for the potential therapeutic use.
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Introduction
Plant cells are capable of producing an overwhelming variety of secondary metabolites, both in terms of 
complexity and quantity. These small organic molecules allow plants to cope with various types of stress, 
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and often have biological activities benefi cial to 
humans that make them of high commercial inter-
est to the biotechnology industry.1 Attempts have 
been made to make this overwhelming variety of 
compounds economically accessible by introducing 
the biosynthesis pathways of interesting natural 
products from higher plants into other organisms, 
for example yeast cultures.2 This perspective dis-
cusses the benefi ts of a recently established produc-
tion organism, the moss Physcomitrella patens, as 
a host for the production of terpenoids.
Plants containing pharmaceutically active natu-
ral products have been used worldwide in folk 
medicine since at least 4000 BC.3 More than 80,000 
of the 250,000 known species of higher plant are 
used in medicine,4 and since some of these plants 
are threatened by extinction, much effort has been 
put into identifying the active compounds before 
their natural source disappears. The plants have 
often been used without knowing the exact mecha-
nism by which the active compound exerts its effect. 
This is still true for several well-known chemical 
groupings of natural products, such as certain sapo-
nins, flavonoids and ginkgolides from Ginkgo 
biloba and Panax ginseng.5 However, for an 
increasing number of plants the pharmacological 
activity has been linked to one or more specifi c 
metabolites. Plant used in traditional medicine has 
been subjected to many different studies, ranging 
from antimicrobial,6 antimalarial,7 and to more 
advanced studies including clinical trials of either 
extracts or isolated compounds.8 A range of these 
isolated natural products have been pursued as 
pharmaceutical drugs, and a limited number have 
been successful.5,9 Many of these biologically active 
compounds from plants are isoprenoid molecules. 
At the end of 2006, more than 50,000 isoprenoid 
structures had been identifi ed, of which many have 
known biological activities.10 Several of these iso-
prenoids have anti-tumor activity, including the well 
known Taxol (paclitaxel), which is originally 
extracted from pacifi c yew trees.9 Novel drugs are 
often in high demand, which leads to a high harvest 
pressure on the source of the drug such as the wild 
plants. As has already been seen in the cases of 
Taxol and the anti-malaria drug, artemisinin, one 
cannot only rely on the wild population for the 
supply of drugs.11 There are several problematic 
issues regarding the collection of wild plants, and 
the fact that pharmaceutical companies need a 
secure and regular supply of plants if they are to be 
used for drug production, steers commercial 
research away from “diffi cult” plants, which cannot 
be cultivated with high yields.12 This is one of the 
major challenges for the development of the very 
promising drug candidate thapsigargin.13
A thapsigargin derived drug is currently 
undergoing clinical trials for the treatment of 
breast, kidney and prostate cancer.14,15 Thapsigargin 
induces apoptosis in mammalian cells by inhibiting 
the sarco/endoplasmatic calcium ATPase (SERCA), 
resulting in an elevated cytoplasmic Ca2+ level, 
which eventually leads to the death of the cell.16 
The crystal structure of the SERCA pump in which 
thapsigargin was bound inside the transmembrane 
pore showed large conformational changes when 
compared with the structure of SERCA with bound 
Ca2+.17 This comparison provided some of the 
information needed for later design of the 
cell-targeted pro-drug based on thapsigargin that 
is now in clinical trials.14–16 At the present time all 
of the commercially available thapsigargin is 
obtained from intact fruits and roots of Thapsia 
garganica L. plants that are collected from the 
wild. The potential increasing worldwide demand 
for thapsigargin is endangering the sparse popula-
tions of T. garganica and other Thapsia species in 
the Mediterranean area and may lead to their 
extinction. Thapsia and Apiaceae plants in general 
are difficult to germinate from seed and to 
maintain under greenhouse conditions.13,18 Jäger 
et al.19 are the only researchers to have reported 
the establishment of in vitro cultures of T. garganica 
for the purpose of producing thapsigargins. They 
induced somatic embryos that accumulated two 
thapsigargins, namely nortrilobolid and trilobolid; 
the ability to convert somatic embryos into plant-
lets was not investigated. To date, there has been 
no report of the successful regeneration of 
T. garganica plantlets in vitro.20
Micropropagation of T. garganica has also been 
investigated as an option for conservation purposes 
as wild populations of the plants are becoming 
increasingly sparse.13 Results show that optimiza-
tion of in vitro propagation of Thapsia for large 
scale production could be very diffi cult indeed. 
This is consistent with reports that acclimatization 
of plants from the Apiaceae family in general is 
very diffi cult to achieve.18,21 Nevertheless, in vitro 
propagation could serve as a way for the conserva-
tion of the medicinally important species, 
T. garganica.20 Another possible method by which 
thapsigargin could be obtained is by chemical 
synthesis. However, although thapsigargin can be 
3Perspectives on using physcomitrella patens as an alternative production platform for thapsigargin
Perspectives in Medicinal Chemistry 2009:3
chemically synthesized, it is not in any way 
commercially feasible at the moment.22
Given the diffi culties associated with the supply 
of thapsigargin from wild plants, the inability to 
cultivate Thapsia garganica effi ciently, and the 
expense of chemical synthesis, an alternative 
production platform needs to be developed to meet 
world market demand.16,20 Previously, attempts have 
been made to transfer the sesquiterpene biosynthetic 
pathway to bacteria or fungi; these have been some-
what successful.10 Recently the group of J. Keasling 
reported the successful generation of a yeast strain 
producing the artemisinin precursor amorphadiene.2 
One of the major obstacles for metabolic engineer-
ing in microorganisms is to obtain functional expres-
sion of P450’s. Yeast is generally considered to be 
a better host for this, owing to its eukaryotic mem-
brane structure.23 Simple pathways such as the three 
steps for the formation of amorphadiene are likely 
to be successful in yeast, whereas more complex 
pathways such as the 19 step taxol biosynthesis are 
much more complex and diffi cult to predict. With 
microbial engineering some of the critical elements 
for stable production are: Choice of host strain, 
expression level, codon-bias, N-terminal modifi ca-
tions and choice of reduction partners, all of equal 
importance.23,24
To achieve such success, an in-depth understanding 
of the original biosynthesis pathway of the target 
molecule is of great importance. The primary 
metabolism of terpenes and especially sesquiter-
penes is gradually being elucidated and issues such 
as compartmentation (Fig. 1) have been observed 
to be of vital importance.3,25 When transferring 
biosynthetic pathways from one kingdom to another, 
the correct localization of introduced enzymes and 
other regulation issues can create problems as 
observed with plant P450s expressed in microorgan-
isms.10,23 Although these problems can be overcome 
as they are encountered, it is possible that they could 
be avoided by using other host organisms like the 
moss, Physcomitrella patens, or by using cell 
cultures as is done with Taxol production.12 Attempts 
at using yeast strains for the production of 
amorphadiene, an artemisinin precursor have been 
somewhat successful, but for small natural products 
several obstacles have to be addressed as outlined 
above. Yeast utilizes several regulatory mechanisms 
to maintain tight control over the intracellular level 
of farnesyl diphosphate (FPP), the central precursor 
to nearly all yeast isoprenoid products and an 
essential building block for sesquiterpenes.26 
High-level production of non-native terpenoids 
requires that FPP fl ux is diverted from production 
of sterols to the heterologous metabolic pathway. 
To do so, expression of the gene encoding squalene 
synthase (ERG9), the fi rst committed step in sterol 
biosynthesis, can be down-regulated. Under certain 
culture conditions, the production of amorphadiene 
was increased fi ve-fold by ERG9 repression.26 The 
isoprenoid pathway in the plastid and in the cytosol 
supplies precursor for mono- and sesquiterpene 
biosynthesis and an array of other compounds, 
many of which are crucial to plant growth and fi t-
ness such as sterols, gibberellins, carotenoids and 
chlorophyll.27 Thus, strong and constitutive expres-
sion of introduced genes could be most harmful. It 
is therefore highly recommended in future metabolic 
engineering experiments to direct gene expression 
to a specifi c tissue or organ or use an inducible 
system, as observed with taxadiene production in 
Arabidobsis.28
The Benefi ts of the Moss 
Physcomitrella Patens
The moss lineage diverged from vascular plants 
about 450 million years ago and has maintained a 
small and rather simple vegetative body structure 
with few specialized cell types.29 Unlike vascular 
plants, the haploid gametophyte dominates the life 
cycle, while the diploid sporophyte is short-lived 
and completely dependent on the gametophyte.30 
Cytoplasm Plastids
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Figure 1. Overall sketch of the two IPP/DMAPP producing pathways 
and their intracellular localization in plants. Arrows indicate the overall 
pathway; many intermediates and additional substrates such as ATP 
and NADPH are omitted. The possible crosstalk between pathways 
is also marked with arrows. GPP: Geranyl diphosphate (C10), 
FPP: Farnesyl diphosphate (C15), GGPP: Geranylgeranyl 
diphosphate (C20).3,51
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Physcomitrella patens has been used as a model 
for studies on plant evolution, development and 
physiology for more than 40 years. However, the 
recent release of the full genome sequence has 
sparked an enormous interest in this plant, which 
is also increasingly being used in biotechnology for 
safe production of complex biopharmaceuticals.31,32 
One example is the production of the highly 
glycosylated peptide hormone erythropoietin 
(EPO).33 Production of EPO was carried out in a 
Physcomitrella Delta-fuc-t Delta-xyl-t strain, 
deficient in the enzymes responsible for the 
plant-specifi c core-bound alpha 1,3-fucose and 
beta 1,2-xylose. Thus, the fi nal product will have 
a humanized glycosylation pattern and therefore 
be non-immunogenic.33,34
Physcomitrella has a number of features that 
make it an attractive production system when 
compared with other plant production hosts. 
Physcomitrella can be grown in sterile cultures 
using standard plant tissue culturing techniques. It 
grows photoautotrophically in a simple inorganic 
media without the need for phytohormones, 
vitamins or a carbon source.35 It can be maintained 
on solid media or as liquid cultures in fl asks or 
fermenters. Unlike other plant production systems 
where liquid cultures are normally composed of 
cells from undifferentiated callus, large continuous 
Physcomitrella cultures can be maintained as 
protonema (the haploid phase).36 In contrast to 
callus cultures, in which undifferentiated cells have 
a high level of somaclonal variation, a culture 
consisting of protonema has a stable genetic 
background, ensuring that the genetic composition 
of continuous Physcomitrella cultures does not 
change over time.31 In addition, Physcomitrella 
has proved to be very tolerant to a number of abiotic 
stresses.37 This high level of tolerance could ensure 
that the Physcomitrella production strain will be 
less affected in fi tness during the biosynthesis.
The protonemal state can be maintained by 
continuously splitting the tissue into smaller pieces 
using a propeller fi tted with blades. Cultivation in 
suspension allows scaling up of biofermenters to 
several thousand liters and the minimal media, 
which contains only minerals and water, enables 
high volume and low cost, and minimizes the risk 
of contamination. An additional advantage is that 
unlike any other plant known to date, Physcomitrella 
performs homologous recombination with high 
effi ciency.38 This allows effi cient and precise gene 
deletions, replacements and insertions and permits 
us to make specifi c and controlled recombination 
events that generate transformants with predict-
able properties. Thus, development of a stable 
production strain does not require crossing steps 
or regeneration of whole plants.39 Combined with 
the Cre-lox technology, high throughput production 
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Figure 2. The proposed formation of eudesmanolides and guaianolides from costunolide in Chicory.49,50
5Perspectives on using physcomitrella patens as an alternative production platform for thapsigargin
Perspectives in Medicinal Chemistry 2009:3
strains with a defi ned background lacking the 
antibiotic resistance marker can be generated.38 
The availability of several characterized constitu-
tive or inducible promoters will further assist in 
the formation of useful production strains.40–42
Ease of handling, simple life cycle and growth 
conditions, and the unique molecular tools available 
for gene targeting make the moss Physcomitrella 
an ideal candidate for the production of natural 
products that are diffi cult to access through other 
means. A potential challenge in the production of 
high levels of secondary metabolites is secretion 
into the media. Wild type Physcomitrella is able to 
secrete large amounts of the tetracyclic diterpene, 
16α-hydroxykaurane, which forms needle-like 
crystal structures when Physcomitrella grows on 
solid media in sealed containers.43 This demon-
strates that the capacity exists within Physcomitrella 
for the processing of terpenoid metabolites through 
secretion of the compound in large quantities. To 
utilize this pathway one should think of a knock-out 
the original diterpene production.44
Combinatorial Biosynthesis in Moss
Combinatorial biosynthesis has already been 
successfully employed in micro-organisms for 
the production of compounds such as novel 
antibiotics.45,46 An in vivo combinatorial biosyn-
thesis approach is pursued in Physcomitrella, 
primarily to obtain new and known natural prod-
ucts with useful biological activity. The generation 
of a moss that produces thapsigargin would add to 
our library of mutants, and secure a stable supply 
of chemically related and robust drugs. Following 
the establishment of such a model of Physcomitrella 
patens, the production of thapsigargin could be 
further enhanced by utilizing the knowledge of 
carbon and other important atom fl uxes within 
plant cells.
In addition to thapsigargin and artemisinin, 
other sesquiterpene lactones are of interest as 
therapeutics. One such compound is parthenolide, 
a well-studied sesquiterpene lactone that is the 
major active compound in the medicinal plant 
Tanacetum parthenium (feverfew) and very prom-
ising as a cancer drug.47 Tanacetum parthenium is 
currently used as herbal remedy to relieve migraine, 
to help prevent blood clots, as an anti-infl ammatory 
for relief in cases of arthritis, to relieve some 
types of menstrual problems, and as a digestive 
aid.48 Interestingly, parthenolide may be one of 
the precursors for thapsigargins (Fig. 2).49,50 
Both artemisinin and thapsigargin are currently 
obtained by extraction from plants. Given their 
wide range of potential medical applications, the 
demand for these compounds is likely to vastly 
exceed the current levels of the current production. 
An important additional outcome of this concept 
is that knowledge obtained during the establishment 
of a Physcomitrella strain producing a thapsigargin 
precursor will enable the design of several other 
drug-candidate-producing moss strains, especially 
within the chemical class of sesquiterpene 
lactones.
With the results that we currently are verifying 
in our lab we believe that the fi rst simple structures 
can be produced within one year, with increasing 
complexity of the molecules produced in the fol-
lowing years. In conclusion, the possibilities of 
using Physcomitrella as a new production platform 
for plant-derived natural products are numerous 
and interesting. While several issues need to be 
addressed and are currently being so, the future 
remains promising, and various kinds of natural 
products could be produced in this simple and 
easily grown plant.
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